Heterocyclic derivative as sting (stimulator of interferon genes) activator and pharmaceutical composition comprising same

Heterocyclic derivative compounds are developed to activate the STING pathway, addressing the need for enhanced anti-tumor immune responses and improving cancer treatment outcomes by converting cold tumors into hot tumors.

WO2025057126A1PCT designated stage expired Publication Date: 2025-03-20SAMJIN PHARMA CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/058923
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-15
Filing Date
2024-09-13
Publication Date
2025-03-20

Smart Images

  • Figure IB2024058923_20032025_PF_FP_ABST
    Figure IB2024058923_20032025_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a heterocyclic derivative useful as a STING activator, a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, a method using same for preventing or treating diseases in which STING activity regulation is beneficial, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Heterocyclic amides useful as protein modulators

    US20180105514A1

  • Heterocyclic amide compound, preparation method therefor and use thereof

    US20220267364A1

  • Immunomodulator

    WO2019134705A1

  • Sting agonists and uses thereof

    WO2020132582A1

  • Imidazopyridine derivatives as sting agonists

    WO2022246597A1